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SAF-A: scaffold attachment factor A 
HMM: Hidden Markov Model 
FLIM: Fluorescence Lifetime Imaging Microscopy SIM: Saturated Structured Illumination Microscopy 
STED: Stimulated Emission Depletion 
STORM: Stochastic Optical Reconstruction Microscopy 
PALM: Photoactivation Localization Microscopy 
fPALM fluorescence-based PALM  
SMLM: Single Molecule Localization Microscopy  
SPDM: Spectral Precision Distance/Position Determination Microscopy  
BALM: Binding-Activated Localization Microscopy 
DAB: diaminobenzidine  
ROS: Reactive Oxygen Species   
DAPI: ;ϰ′,ϲ-Diamidino-2- phenylindole dihydrochloride)  
IdU: 5-iodo-2-deoxyuridine 
AO: Acridine Orange 
CARS: Coherent anti-Stokes Raman scattering 
MSI: Mass Spectrometry Imaging   
PWS: Partial-wave spectroscopic 
MTG: MitoTracker Green 
ERTG: Endoplasmic Reticulum Tracker Green   
NETs: Neutrophil Extracellular Traps 
m-AMSA: 4'-(9-acridinylamino) methane sulfon-m-anisidide 
MTX: mitoxantrone 
PK-PD-CD: Micro-PharmacoKinetics and cellular PharmacoDynamics with specific Cellular 
Descriptors  
 
Abstract: 
The nuclear-targeting chemical probe, for the detection and quantification of DNA within cells, has 
been a mainstay of cytometry - from the colorimetric Feulgen stain to smart fluorescent agents with 
tuned functionality. The level of nuclear structure and function at which the probe aims to readout, 
or indeed at which a DNA-targeted drug acts, is shadowed by a wide range of detection modalities 
and analytical methods. These methods are invariably limited in terms of the resolution attainable 
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versus the volume occupied by targeted chromatin structures. The scalar challenge arises from the 
need to understand the extent and different levels of compaction of genomic DNA and how such 
structures can be re-modelled, reported or even perturbed by both probes and drugs. New cytometric 
approaches to analysing chromatin released from cells, as in NETosis, demonstrate the potential for 
probes to report defining features. Typical of recent insights into chromatin organisation is the 
'ChromEMT’ study that exploits the properties of the anthraquinone-based cytometric dye DRAQ5™. 
Insights reveals that local and global 3D chromatin structures in the nucleus determine compaction. 
Cytometry can report on complex levels of chromatin order, disorder, disassembly and active 
disruption. The focus of this review is nuclear cytometry, with linked reference to DNA targeting drugs 
and probes,  their impact in the chromatin environment. 
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Introduction 
͚forŵ eǀer folloǁs fuŶĐtioŶ͛ 
Louis Henry Sullivan (1856 – 1924) 
AŵeƌiĐaŶ aƌĐhiteĐt aŶd ͚fatheƌ of skǇsĐƌapeƌs͛ 
 
Cellular structures, first recognised by von Nägeli in 1842, ǁould lateƌ ďe Đalled ͚Đhƌoŵosoŵes͛ ďǇ 
Waldyer in 1888 to reflect their staining behaviour with dyes. The oďseƌǀaďle paĐkagiŶg of a Đell͛s 
genetic material and its metrology have provided a continuing source of interest through to modern 
cytogenetics. Cytometry in its widest definition has a considerable track record in the analysis of the 
multi-level organisation of the genetic material in eukaryotic nuclei (1-8). Nuclear cytometry-based 
methods can simplify the analysis and quantification of protein associations to chromatin and reveal 
population heterogeneity (9). Recent methods describe the extraction of nuclei for the purpose of 
probing cellular and transcriptional states (10,11) although preserving native chromatin super-
structure remains a challenge. Extensive information is available from academic and commercial 
sources on the spectral properties of molecular probes for nuclear cytometry that can report nuclear 
states. This review will not explore these in detail. However, understanding the balance of advantages 
and limitations is important when a given probe is used for specific purposes or in a sensitive cellular 
system (12,13). Critical factors in live cell studies are the biological impact of the probe and its access 
to a nuclear target determined by chromatin organisation (14). Such factors are shared by nuclear-
targeted drugs in driving their pharmacodynamic effects. Here these aspects are discussed with 
respect to DNA-interactive probes, with linked reference to DNA targeting drugs, in the context of the 
chromatin environment. 
 
Chromatin organisation 
 
Genomic DNA is compacted into chromatin through packaging with histone and non-histone proteins. 
Chromatin folding and packaging has to change dynamically as the cell progresses through the cell 
cycle. Chromatin organisation is addressable by DNA-affinic probes. The challenge is how to recognise 
and measure different scalar levels of chromatin organisation, from base-pair to the whole nucleus. 
The scalar levels of chromatin organisation dictate the analytical approach employed and the extent 
to which a probe can be usefully deployed (Fig. 1). The cell deals with an impressive length of linear 
DNA packaged within its nuclear volume. Towards one end of the scale, haploid yeast cells with a 
ŵeaŶ ŶuĐleaƌ ǀoluŵe of ϯ μŵ3 has a genome length of ~12 Mbp. This represents some 0.3 % of the 
ŶuĐleaƌ ǀoluŵe oƌ aƌouŶd Ϭ.Ϭϭ μŵ3. A human diploid cell nucleus with a volume of around 700 μŵ3 
copes with 3 billion bases and a combined strand length of genomic DNA of  just over 2 m.  
 
There is increasing evidence of a relationship between higher orders of chromatin topology and the 
regulation of global patterns of gene expression (15). One concept is that evolutionary selection 
favours the clustering of widely expressed housekeeping genes. Such clusters adopt an open 
configuration of chromatin structure. Open chromatin fibres have also been found to be enriched in 
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gene-rich domains and not just in those regions that are transcriptionally active (16). The mechanisms 
by which large-scale chromatin structures can be de-compacted or undergo dynamic folding are 
becoming clearer (17). An informative example is how the scaffold attachment factor A (SAF-A) can 
interact with chromatin-associated RNAs in a transcription-dependent manner. SAF-A oligomerization 
de-compacts large-scale chromatin structure while SAF-A loss or monomerization promotes aberrant 
chromosome folding and the accumulation of genome damage (17). This also highlights  a crucial role 
for chromatin organisation in maintaining a stable environment for the genome.  
 
Annotation of the human genome with respect to different chromatin states can reveal signatures for 
functional descriptions. Descriptors can reflect transcription-associated or active large-scale 
repressed states (18). Recently the ChromHMM tool has been described that can seek signatures of 
chromatin-states using a multivariate hidden Markov model (HMM) (19). The tool  performs an 
enrichment analysis of the resulting annotations to allow functional interpretation (19). Advances in 
the high-resolution approaches of electron and super-resolution fluorescence microscopy, together 
with DNA sequencing, have provide views of the relationship between chromatin and nuclear 
machineries within a ͚4D nucleome͛ (20). This approach has provided a finer structural definition of 
active and inactive nuclear compartments. An inactive compartment comprises the core of chromatin 
domain clusters. The active compartment locates at the periphery of these clusters.  A further 
compartment links to routes for nuclear import and export via nuclear pores (20). 
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Figure 1: Probing the hierarchy of chromatin organization 
 
 
At its lowest level, DNA wraps around histone octamers to form nucleosomes but needs to eventually 
compact into discrete chromosomes – with conceptual models for the elaboration of chromatin fibre 
structure supported by in vitro studies (Fig. 1). Chromatin experiences a hierarchy of packaging but 
the models become increasingly speculative as the volume of observation increases. Chromatin 
carries negative charges due to incomplete neutralisation of the DNA polǇŵeƌ͛s phosphate ďaĐkďoŶe 
by basic core histones. The result is that chromatin structure is subject to electrostatic repulsion 
between its neighbouring sections. Chromatin also responds to changes in the electrostatic 
microenvironment which interacts both with negatively charged DNA and the positively charged 
histones. As a result chromatin structure can be manipulated in vitro by simply changing the 
electrostatic environment, frequently by supplying divalent cations. In live cells these fundamental 
properties contribute to a state of fluidity – perceived as a ͚liquid-like behaviour͛ of the 10-nm 
chromatin fibre (21).  The 30-nm chromatin fibre is often regarded as the secondary structure of 
chromatin directed by nucleosomes, nucleosome-protein complexes and regulatory factors (22).  This 
key structure remains controversial both in its form and the extent to which it is adopted in different 
cells types (23,24). However, even at these primary and secondary levels, it is recognised that the 
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chromatin structural environment does not remain static. In live cells chromatin transitions can occur 
on timescales which range from milliseconds to minutes or even hours (25). 
 
For a DNA probe to work is must reach its target. Inadequate target exposure can also be a factor in 
the pharmacodynamic failure of a drug. Predicting access to intracellular targets can involve a label-
free (26) or fluorescent drug-based modelling approaches (27). However, such methods are yet to 
consider the impact of the chromatin ͚laďǇƌiŶth͛ (26). Chromatin structures present an ͚oďstaĐle 
Ŷetǁoƌk͛ foƌ diffusiŶg pƌoteiŶs, effeĐtive over a distance of 1–2 m, providing a temporal restraint on 
interactions with DNA (20). It remains unclear ǁhetheƌ ͚oďstƌuĐted tƌaŶspoƌt͛ thƌough ĐhƌoŵatiŶ 
networks (28) can predict probe/drug access to DNA targets. The caveat is that a probe may be limited 
by the chromatin states it can report – a source of unsuspected bias. The stress responses of chromatin 
control chromatin accessibility to facilitates genome stability (29). For example, the ͚relaxation͛ of 
chromatin at regions of damaged DNA signals damage location and promotes the assembly of repair 
complexes (30). Nucleosomal structure itself can be considered both a ͚central signalling hub’ and a 
‘landing platform͛ in the repair process (31). A range of fluorescence imaging methods can now 
provide descriptions of DNA repair in single cells [review: (32)]. Fluorescent probes for marking sites 
of DNA damage can provide insights into defects in DNA repair.  Such approaches include detection 
of base excision repair intermediates (apurinic/apyrimidinic sites) in DNA (33) and dual-incision steps 
of UV-damaged cellular nucleotides (34) in combination with flow cytometry. 
 
 
Chromatin dynamics 
 
Chromatin remodelling encompasses multiple activities including: DNA replication and repair, 
transcriptional control, epigenetic regulation, programmed disassembly during apoptosis, 
chromosome packaging and segregation. These events are clearly relevant to critical cellular 
transitions in development, neoplastic progression and pluripotency (20,35-37). A current view is that 
regulation of the chromatin nano-environment, over ranges that exhibit chromatin packing-density 
heterogeneity, can allow for a predictable modulation of global patterns in gene expression (38).  A 
͚rational͛ modulation of chromatin density fluctuations can lead to a decrease in global transcriptional 
activity. One can view this as ͚ŵaĐƌogeŶoŵiĐ eŶgiŶeeƌiŶg͛ ǁithiŶ the ŶuĐleus foƌ diƌeĐtiŶg ǁhole-scale 
transcription levels (38).  
 
ATP-dependent nucleosome-remodelling complexes direct histone behaviour through an ATPase-
translocase 'motor' function that mobilises DNA within the nucleosome (39). ATP-dependent enzymes 
that remodel chromatin are therefore important controllers of structure (36,40,41). Key functional 
components of chromatin, along with histones, condensins, cohesins and regulatory proteins (42-44), 
are the distinct class of topology correcting enzymes – the DNA topoisomerases. Chromatin is a store 
of torsional energy which results in the release of negative superhelicity upon decompaction (45). 
Conversely, dynamic changes in DNA supercoiling will dictate packaging and transcription (46). 
Nuclear problems can arise when the replication of chromatin loops generates interlinked DNA 
products (catenanes) or when DNA function requires the resolution of torsional stress. The cell’s 
enzymatic solution is via the DNA topoisomerases. These enzymes provide a co-ordinated process of 
 8 
strand passing within a DNA-enzyme complex (type IA and type IB enzymes). They can also allow the 
movement of an actively-cleaved strand around an intact strand prior to re-ligation (type IB enzymes). 
Type IIA enzymes are ͚full deĐateŶases͛ (40), passing one duplex through a double-strand break 
generated by the enzyme in another duplex. On the other hand, type IA enzymes strand pass single-
stranded DNA segments by the adjacent duplex and thereby locally changing the linking number (40). 
Type IIA DNA topoisomerases are vital for progression through the cell cycle (47). In terms of probe 
manipulation of superhelicity, intercalation can generate changes in local supercoil relaxation states 
with extension of the duplex. A cell permeant biotinylated 4,5,8-trimethylpsoralen probe, that 
preferentially intercalates with DNA enriched in negative supercoils, has been used to monitor 
changes in DNA supercoiling in vivo (45). RNA polymerase and topoisomerase activities remodel DNA 
supercoiling, creating supercoiling domains that affect the folding of large-scale chromatin structures 
(45). 
 
The DNA topoisomerases present specific and demonstrable targets for several classes of both 
anticancer and antibacterial drugs (41). A flow cytometry-based method has been described for the 
high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells (48). 
In mammalian cells the DNA damage signalling responses to DNA topoisomerase inhibition can also 
be tracked by flow cytometry to reveal the restraints on DNA replication and cell cycle progression 
(49-51). The human type IIA enzyme is a target for catalytic inhibitors such as the bis-dioxopiperazine 
ICRF-193.  ICRF-193 induces late cell cycle checkpoint stalling, decatenation inhibition, mitotic 
anomalies or even bypass of mitosis to polyploid states in permissive cells (52).  Recent structural 
analyses indicate how type IIA enzymes embrace the helix DNA and how the enzyme-DNA interactions 
inform drug behaviour (53). The human type IIA topoisomerase pƌoteiŶs, topoisoŵeƌase IIα 
;TopϮalphaͿ aŶd topoisoŵeƌase IIβ ;TopϮďetaͿ, aƌe the taƌgets foƌ seǀeƌal aŶtiĐaŶĐeƌ ageŶts iŶĐludiŶg 
etoposide, the DNA intercalating anthracyclines (doxorubicin, daunorubicin) and the anthraquinone 
mitoxantrone (54). The Đellulaƌ ƌoles of topoisoŵeƌase IIβ (55) and the consequences of inhibition, 
given its expression in terminal differentiation, are less understood compared with the cell cycle 
ƌegulated topoisoŵeƌase IIα. BaĐteƌial tǇpe II topoisomerases (gyrase and topoisomerase IV) are the 
targets of quinolones and aminocoumarin antibiotics (41).  
 
The eukaryotic type IB topoisomerases (Top1) are classically targeted by camptothecin and related 
derivatives such as topotecan or irinotecan. Genome-wide high-resolution mapping has revealed the 
targeting of transcriptionally active genomic regions by the Top1 inhibitor topotecan and the Top2 
inhibitor etoposide. On the hand, daunorubicin induces DNA breaks and evicts histones from active 
chromatin with a ͚ƋueŶĐhiŶg͛ of local DNA damage responses (56). Fluorescence lifetime imaging 
microscopy (FLIM) has been used to map the nuclear docking of topotecan at a subset of DNA sites in 
nuclear structures of live breast tumour cells in which the DNA binding probe DRAQ5 has been used 
to uncover sites of drug interaction (57). The anticancer anthracyclines daunorubicin (daunomycin), 
doxorubicin (adriamycin) aŶd epiƌuďiĐiŶ ;ϰ͛-epi-doxorubicin, an active isomer of doxorubicin), belong 
to a class recogŶized as poteŶt TopϮ ͚poisoŶs͛. Theiƌ aďilitǇ to generate protein-associated dsDNA 
breaks can be detected by cytometric analysis (40). Early studies showed the restricted binding of the 
anthracycline doxorubicin to DNA within chromatin compared to calf thymus free DNA and the ability 
of related drugs to induce compaction of isolated chromatin (58,59). Further evidence indicates that 
anthracycline antibiotic exposure can lead to chromatin unfolding and aggregation (60), DNA torsional 
changes (61) and histone eviction from open chromatin (62). Such drugs are also self-reporting probes 
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for cellular and nuclear micro-pharmacokinetics enabled by their intrinsic fluorescence tracked in real-
time by flow cytometry (63,64).  
 
 
Resolving chromatin organisation:  
 
Super Resolution Optical Microscopy  
New developments in fluorescent sensors based on small-molecule dyes or fluorescent proteins (13) 
are in parallel with expanding options for advanced microscopy methods for visualizing chromatin 
structure (4). Fluorescent sensors for monitoring proteins, DNA, RNA, small molecules and ions (e.g. 
Zn2+) can all exploit super-resolution microscopy (13). Some of these approaches are noted briefly 
here. Super-resolution fluorescence microscopy encompasses multiple techniques (65) that are 
applicable to probing chromatin structure (4,66-70). Super-resolution microscopy effectively breaches 
the diffraction limit of optical microscopy and efforts continue to accrue techniques reaching signal 
resolution at length scales of sub-20 nm. Typical approaches employ the principles of patterned 
illumination light, such as Saturated Structured Illumination Microscopy (SIM) and Stimulated 
Emission Depletion (STED). Alternatively, some methods such as Stochastic Optical Reconstruction 
Microscopy (STORM), Photoactivation Localization Microscopy (PALM), and fluorescence-based 
fPALM allow for single molecule detection and localization applicable to the imaging of chromatin 
organisation (4). Approaches include the use of a fluorescent label to image DNA and chromatin in 
situ at the single-molecule level (71-73). A recent application of the DNA dye Vybrant®DyeCycle Violet 
with single molecule localization microscopy (SMLM) has generated images of DNA in nuclei of fixed 
mammalian cells (74). It is estimated that using fixed whole cells and standard DNA dyes, a structural 
resolution of chromatin is attainable of the order of 50-100 nm using SMLM (72). The use of Spectral 
Precision Distance/Position Determination Microscopy (SPDM) has the potential to reveal nuclear 
nanostructures down to few tens of nanometre resolution (75). Several intercalating and minor-
groove binding DNA dyes can be used to register (optically isolate) a few DNA-binding dye signals at a 
time using a variation of Binding-Activated Localization Microscopy (BALM) (71). We should also 
remember that unmodified nucleic acids can show stochastic fluorescence switching at physiological 
concentrations under visible light illumination. This presents an opportunity for label-free super-
resolution imaging of DNA directly (76). However, at this stage super-resolution approaches cannot 
address the problem of how to visualise and reconstruct chromatin ultrastructure through large 3D 
volumes of intact cells – a problem familiar in cytometry. 
 
ChromEMT 
The practical limits on imaging resolution restrict the ability to visualise chromatin organisation in situ 
for informative 3D volumes. A recent report has broken through this analysis barrier for intact cells 
using a new method. ChromEMT enables DNA and chromatin ultrastructure to be visualized and 
reconstructed unambiguously through large 3D volumes (77). The ChromEMT method combines 
electron microscopy tomography (EMT) with a labelling method that selectively enhances the contrast 
for DNA structures.  The ChromEMT technique exploits  unique properties of the fluorescent 
anthraquinone DNA dye DRAQ5, which upon photon-activation can catalyse the deposition of 
diaminobenzidine (DAB) polymers on the chromatin surface, enabling structures to be subsequently 
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visualized with OsO4 in EM [Figure 2; (77)]. DAB photo-oxidation has been used in a range of studies 
that correlate light and electron microscopy, for nanoparticle location and the residence of low levels 
of photosensitizing molecules (78). Advances in multi-tilt EMT have allowed researchers to reveal the 
chromatin ultrastructure and 3D packing of DNA in both human interphase cells and mitotic 
chromosomes. Critically, it appears that there is a disordered nature of the chromatin chains revealed 
by ChromEMT. These chains are flexible, bending and folding into different packing densities. Dynamic 
changes in packing density provide opportunities to fine tune accessibility to DNA sequences, 
nucleosome variations and chromatin modifications. These variations in packing density will be 
important at both local and global levels within the intact nucleus. This opens a new level of 
organisation or indeed dis-organisation for exerting control over function. The anthraquinone dye 
used in ChromEMT recalls a lineage of molecules that link probe and drug properties employed in 
nuclear cytometry. 
 
 
 
 
 
 
 
 
Figure 2. ChromEMT: Jablonski energy diagram of DRAQ5 excitation, fluorescence and the formation 
of a triplet excited state generating reactive oxygen species (ROS) that enable subsequent chromatin 
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visualisation at low scalar distances. Diagrammatic sequence shows the photo-oxidative catalysis of 
the deposition of osmiophilic DAB polymers on DNA in chromatin in situ (77). 
 
 
Nuclear cytometry: DNA reporting  
 
The measurement of cellular DNA content, a common laboratory procedure (12,79), has been 
dependent upon the stoichiometric reporting capacity of fluorescent nucleic acid-affinic dyes.  
In terms of nuclear cytometƌǇ,  seǀeƌal Đlasses of ͚ǀital͛ DNA fluoƌesĐeŶĐe pƌoďes, iŶ additioŶ to the 
bis-ďeŶziŵidazoles HoeĐhst™ dǇes offeƌ the aďilitǇ to eǆploƌe ĐhƌoŵatiŶ dǇŶaŵiĐs iŶ liǀe Đells. This 
eǆpaŶdiŶg palette of pƌoďes iŶĐludes: SǇtoϲϭ™, D‘AQϱ™ aŶd VǇďƌaŶt® DǇeCǇĐle™. The interactions 
of a range of fluorescent dyes such as quinacrine, Hoechst 33258 (80), daunomycin, chromomycin A3 
and 7-aminoactinomycin D with DNA offer multiple probe-based approaches for exploring chromatin 
structure (5). A recent addition to the suite of small-molecule fluorophores is the near-infrared (IR) 
silicon-rhodamine dyes with spectral properties that aid in vivo imaging (81). Spectral analysis can 
reveal modes of binding, sequence selectivity, probe interactions, consequences of fixation and 
selectivity of nuclease digestion. At a fundamental level, probe performance can be expected to obey 
the law of mass action in relation to unbound fluorochrome concentration (12). In studies on 
anticancer drugs there is always the possibility of interaction between the drug and the fluorochrome 
used to simultaneously probe DNA content. Since some of the DNA-binding drugs are fluorescent, 
their emission can directly overlap with that of the probe, through Förster resonance energy transfer, 
and affect the efficiency of probe detection (82).  
 
With all probes there are caveats. Prolonged exposure of live cells to the nominally non-permeable 
dye propidium iodide (PI) reveals a background granular distribution of the probe in the cytoplasm, 
consistent with accumulation in endosomes, and also dye binding to nucleolar RNA in live cells (83). 
DAPI ;ϰ′,ϲ-Diamidino-2- phenylindole dihydrochloride) is usually referred to as a semi membrane-
permeant dye because of its reduced penetration through viable cell membranes but it is 
concentration sensitive with respect to toxicity especially at levels for attempts at DNA content 
reporting (84). A non-permeable very low toxicity dye, such as DRAQ7, offers the opportunity to 
monitor subpopulations of cells that lost cellular barriers to chromatin access but without perturbing 
the viable cell fraction (85). This approach is particularly useful when monitoring transitions in cell 
behaviour (86). In the case of the of vital cell dyes, problems of cell proliferation inhibition (14) and 
phototoxicity (87) can arise, but these effects will be time, dose and system dependent. The 
anthraquinone DRAQ5 when used at levels that reveal efficient DNA content reporting in live cells can 
interfere with the binding of H2B core histones to DNA, not observed after binding to DNA of a minor 
groove binder Syto17 (88,89). Hoechst 33342, DRAQ5, and DyeCycle Violet induce various degrees of 
DNA damage responses and cell cycle changes, which should be a matter of concern when using these 
dyes as supravital DNA probes inappropriately (90). Photo-toxicity of dyes is an issue. This is 
particularly the case a shorter wavelengths as observed with UV-excited Hoechst 33342 in time-lapse 
fluorescence microscopy (87). However, this known ͚adǀeƌse͛ effeĐt of UVA iƌƌadiatioŶ oŶ dǇe-treated 
cells can be used to investigate the kinetics of dye residence at critical chromatin sites capable of 
generating photo-induced DNA-protein crosslinks (91). The potential for photosensitisation is 
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appreciated in the context of photothermal therapy (PTT) and photodynamic therapy (PDT). Here 
there have been recent advances in the synthesis and application of NIR-absorbing organic 
ŶaŶopaƌtiĐles as phototheƌapeutiĐ ͚ŶaŶoageŶts͛ (92).  
 
Small DNA-affinic molecules can be used to reveal not only DNA content but also accessibility within 
higher orders of chromatin structure. This opportunity was recognised in earlier cytometry studies 
(93) by exploiting the metachromatic properties of acridine orange (AO) (94,95). Many of our current 
methodological approaches and signal interpretations were developed using this cytometric probe. 
Differences in chromatin structure can be revealed by the metachromatic effects detecting DNA 
‘melting’ – the differential susceptibility of DNA in situ to undergo denaturation upon exposure to heat 
or acid. Differential stainability of dsDNA (green fluorescence) versus ssDNA (red fluorescence) with 
AO made it possible to discriminate between G0, G1, S, G2 and M cells (94,95) (Fig. 3). Multiple 
cytometry techniques have been applied to cell cycle profiling, including exploitation of chromatin-
protein bindings events, chromatin modification and the nuclear translocation of cyclins. DNA content 
and chromatin-bound proteins to reveal sub-phases in G1 (96). Mass cytometry using 5-iodo-2-
deoxyuridine (IdU) can co-mark cells in S phase using cyclin antibodies and the phosphorylation 
patterns a specific histone H3 (97). Live cell tracking of a cyclin B1-GFP sensor can detect cell-cycle 
phase routes to mitotic traverse, arrest or endoreduplication confirmed by flow cytometric mapping 
using DRAQ5 (98). 
 
 
 
 
Fig. 3. Cytometric analysis showing differences in chromatin structure of lymphocytes in different 
phases of the cell cycle. Sub-sets revealed by changes in susceptibility of DNA to denaturation induced 
by acid followed by differential staining of dsDNA versus ssDNA with metachromatic fluorochrome 
acridine orange (AO). (A) Unstimulated cells, (B) cells stimulated with phytohemagglutinin (PHA) for 
18 h, (C) cells stimulated for 3 days, (D) cells stimulated for 3 days; vinblastine included in the cultures 
for the final 6 h to arrest cells in mitosis. Evident is the transition (T) cells from G0 to G1 after 18 h, 
associated with an increase in green fluorescence and a decrease in red.  Subpopulations of cells in G0, 
G1, S, G2 and M can be distinguished based on changes in green and red fluorescence (94,95). 
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Fluorescent dye-chromatin interactions borrow from the experience with chromosome banding. 
These can reveal the spectacular capacity of cells to show shifts in chromosome organisation at its 
highest levels (99,100). At a highly practical level, metachromatic staining by AO reveals any defective 
packaging of DNA in chromatin of infertile sperm cells (101). Fig. 4 shows the classic flow cytometry 
methodological study of human fertile versus infertile sperm cells (102). Defective packaging of DNA 
correlates with DNA fragmentation, not unlike that seen in apoptotic cells (103,104). This 
methodology was adopted in clinical practice for detecting fertility status of human males and in 
animal husbandry (105,106). 
 
 
 
 
Figure 4. Susceptibility of DNA to denaturation as detected by staining with AO reveals the presence 
of human sperm cells with defective chromatin structure (H) correlated with infertility. Bivariate 
frequency distribution histograms representing intensity of total fluorescence (Tot. Fl.; red+ green) 
versus αt (ratio of red to total fluorescence intensity) of two samples of sperm cells, one characterized 
by a small fraction of cells with high sensitivity of DNA in situ to denaturation (left) and the other with 
a higher proportion of such cells (right). The borderline discriminating between the cells characterized 
by low (L) and high (H) sensitivity to denaturation (at, index) is marked by thick arrows. The frequency 
of H cells in infertile subjects was shown to be correlated with frequency of cells with fragmented DNA 
detected by the TUNEL assay (103). 
 
In the native nucleus, the extent and modes of binding of DNA interacting agents are informed not 
only by agent properties and chromatin access but also by cellular routes for handling small molecule 
probes. For example, contrast to fixed cells, live cells exposed to AO at low concentrations (<5 M) 
selectively accumulate the probe in acidic vesicles, including lysosomes where it luminesces red, and 
is not a useful chromatin probe (107,108). The situation is complicated further by dynamic chromatin 
structures responding to the presence of a probe/drug itself and linked downstream stress responses. 
Not surprisingly there is significant interest, in both nuclear cytometry and anticancer targeting 
strategies, to gain an understanding of critical chromatin structures and their perturbation. 
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Nuclear cytometry: alternatives  
 
Not all methods depend upon the intrinsic or enhanced fluorescence of a probe or indeed that of a 
nuclear-locating drug. Mass cytometry has exploited metal-based unique signals for DNA-affinic 
molecules for: the study of cellular uptake and the linked anticancer effects of platinum-containing 
drugs (109), the use of cisplatin-antibody-conjugates for immunophenotyping (110) and the 
incorporation of a platinum-based covalent reagent to act as a discriminator in cell viability 
measurements (111). Alternative detection modalities can assess the subcellular disposition of 
reporter probes. Raman spectroscopy as applied to microscopy has been used to measure the 
chemical signature of a sample or identify the presence and quantity of a molecular species (112) 
(Figure 5). The characteristics and behaviour of a probe can in turn be used to extract biological 
information via the state of the probe at specific locations. The two typical methods of collecting the 
Raman spectral data to generate images are Raman mapping and Raman imaging. Raman mapping 
collects a spectral hypercube (a Raman spectrum from each position on the sample in a single file), 
rather than a simple intensity image. The hypercube is analysed to produce Raman images. There are 
several Raman mapping methods, including point-by-point mapping and line focus mapping. Here, 
there is a balance between under-sampling and acquisition time for sample regions of interest. Spatial 
resolution is determined by a combination of the laser spot size and the spacing between acquisition 
points on the sample (e.g. sample stage step sizes down to 100 nm). On the other hand, Raman 
imaging allows for rapid acquisition, by collecting spectral intensity values simultaneously from an 
entire region of interest, especially if high laser power is available. However this approach yields 
limited information with an ultimate resolution to a little under a micrometre. 
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Figure 5: Diagrammatic representation of some of the light scattering modes of interest and the 
differential detection of a Raman signature for a cell permeant DNA binding probe. The more 
familiar Rayleigh scattering can be described as ͚elastic͛ scattering since the photon energies of the 
scattered photons are not changed. When a Raman active probe is irradiated with photons of a 
selected frequency, that avoids peak fluorescence excitation, a minority of the incident photons 
interact with a vibrational mode of the irradiated probe and are ͚inelastically͛ scattered. The 
inelastically scattered photons are shifted in frequency. This shift can be to a higher frequency (anti-
Stokes) or to a lower frequency (Stokes). The frequency versus intensity Raman spectrum provides a 
unique detection signal for the probe at a selected location. (Acknowledgement: exemplar data for 
DRAQ5 provided courtesy of L Jamieson, D Graham & K Faulds, Centre for Molecular Nanometrology, 
Department of Pure and Applied Chemistry, University of Strathclyde, UK). 
 
Many materials have characteristic Raman spectra, with a growing number of applications within 
biology. The approach can provide chemical and compositional information and does not typically 
suffer from interference from water molecules. Further, cellular components, including DNA, have 
distinct intrinsic Raman scattering spectra (113). Chromatin density variation among the individual 
sub-phases of mitosis affect Raman and infrared micro-spectroscopic intensities (114). Label-free DNA 
imaging in vivo has been demonstrated using stimulated Raman scattering microscopy (115,116). 
Hyperspectral Coherent anti-Stokes Raman scattering (CARS) microscopy (117) can be used to provide 
label-free quantitative volumetric imaging of cell composition defined in terms of water, protein, 
chromatin and lipids (Fig. 6). 
 
 
Figure 6 Hyperspectral CARS of a mitotic cell - detection of key cellular components and their spectra 
in a human osteosarcoma cell. Cells ǁere iŵaged iŶ ϯD iŶ the CH stretĐhiŶg ǀiďratioŶal raŶge ;ω=Ϯϰ00-
3800 cm-1) using a 60X 1.27NA water objective and 1.4NA oil condenser. The point spread function 
(PSF) informs the imaged volume for chemical components [volume dimensions of approximately 0.3 
µm lateral and 0.9 µm axial full width at half maximum (FWHM)]. Note that the imaged volume 
contains about 95% water. Y axis shows hyperspectral averaged �(χͿ  data (118). To analyze the data, 
a three step method was applied which includes singular value decomposition (SVD), phase corrected 
Kraŵer͛s KroŶig ;PCKK)(118) and factorization into susceptibilities and concentrations of chemical 
components (FSC3) [(a: blue = water; b: green = protein; c: red = DNA)]. (Unpublished: exemplar data 
by A Karuna, F Masia, P Borri, R Errington, and W Langbein at the Schools of Physics, Biosciences and 
Medicine, Cardiff University, UK). 
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Mass Spectrometry Imaging (MSI) can qualitatively describe drug distribution in 2D tissue sections 
while 3D MSI can reveal the heterogeneity in tumours (119). MALDI imaging mass spectrometry has 
been applied to the analysis of the spatial distribution of histone modifications in tissues (120), with 
recent studies achieving high lateral resolution of the order of 5 micrometre approaching a cell-to-cell 
methodology. Partial-wave spectroscopic (PWS) microscopy is a label-free quantitative imaging 
technique (resolution range of 20 and 200 nm), capable of tracking  changes in chromatin structure 
after DNA damage in live cells (121). This approach reveals that UV-excited Hoechst 33342 can cause 
damage to chromatin within seconds. Over a time-frame of minutes, the dye itself can cause a global 
alteration in chromatin nano-architecture independent of its excitation (121). PWS microscopy reveals 
the  not unexpected chromatin disrupting effects of fixation (122). This disruption highlights the 
relevance of live cell imaging techniques, or the advantage of cryo-fixation, when exploring native 
chromatin organisation (122). The ability to combine PWS microscopy with fluorescence confocal 
microscopy for the co-localization of cellular nanostructures is a welcome route for functional 
annotation (123). Alternative modes of light interaction with DNA dyes can be exploited in nuclear 
cytometry. For example, the unique light absorption properties and high DNA affinity DRAQ5 (124) 
coupled with low fluorescence quantum yield (125), have been exploited in hybrid ultra-high 
frequency acoustic/photoacoustic microscopy. The geŶeƌatioŶ of photoaĐoustiĐ sigŶals fƌoŵ a Đell͛s 
nuclei reveals gross conformation and nuclear dimensions (126).  
 
 
Apoptosis, autophagy & NETs 
 
Chromatin disassembly is a feature of the various cell death processes and will only be discussed here 
briefly. Multiple cytometric methods can track the irreversible apoptotic process of chromatin 
disassembly (127,128) and real time progression to the ‘fait accompli’ of plasma membrane disruption 
(85). In the case of apoptosis, nuclear DNA undergoes extensive fragmentation and release from the 
cell within apoptotic bodies (42). RNA and DNA are segregated and packed into separate apoptotic 
bodies (129) detectable in peripheral blood (130). Specialization of phagosomes of macrophages 
facilitates heterophagic degradation of nucleic acids during apoptosis (129). An exciting and emerging 
area is the balance between autophagy, providing an environment for cell survival, versus the 
enactment of cell death processes via apoptosis. The cell survival and housekeeping process of 
autophagy involves the breaking down and reusing of cytoplasm components. Fluorescence 
microscopy and flow cytometry is commonly used to study autophagy of discrete structures such as 
mitochondria (131) and lysosomes (107). Flow cytometric methods are also available to detect the 
linked changes in organelle mass using MitoTracker Green (MTG) and Endoplasmic Reticulum Tracker 
Green (ERTG) (132). Evidence is mounting that there is cross-talk between the dysfunction of 
apoptotic and autophagic pathways in disease states including neurodegeneration (133) and cardiac 
pathology (134). Participants in this cross-talk are modifications to histones, providing critical 
structural codes (135).  
 
Chromatin ͚function͛ oƌ ƌatheƌ ͚ǀalue͛ ĐaŶ extend beyond the cell͛s boundary (136) presenting a 
distinct focus area for cytometry. The cell death process termed NETosis, creates homogenised 
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chromatin together with granule proteins that undergo release from actively disintegrating neutrophil 
granulocytes. A variety of triggers promote NET formation. These chromatin structures form a 
tethered extracellular mesh (Neutrophil Extracellular Traps; NETs; (137)). NETs enmesh and degrade 
virulence factors and kill bacteria. The DNA backbone of NETs is  vulnerable to extracellular DNase 
digestion. Although NETosis is distinct from apoptosis and necrosis, there is conflicting evidence of its 
dependence on autophagy for extracellular DNA trap formation (138,139). Further there is a 
distinction between the formation of NETs from mitochondrial of nuclear DNA (140). Nuclear 
chromatin-originating DNA masses are less structured (the DNA mass being some 3-5-fold greater in 
volume than condensed chromatin) and less beneficial for antimicrobial trapping (141). The more 
structured mitochondrial originating NETs are built around the tight packaging of mtDNA as nucleoids 
and their organization into higher-ordered assemblies (142).  
 
Developing cytometric methods that distinguish different NET origins and structures have applications 
in measuring inflammatory vascular injury and tissue damage (143) and in a variety of disease 
processes including autoimmunity, thrombosis, cancer and antiviral responses (144). NET formation 
has been examined using correlative microscopy - combining TEM, SEM, immunofluorescence and live 
cell imaging techniques (145). Such imaging approaches can be supported by automated image 
quantification software (146). A range of probe-based methods are also available for quantifying 
NETosis (145,147). They include flow cytometry and staining with the plasma membrane-
impermeable DNA-binding dye SYTOX Green and its correlation with image-based detection (148). Co-
staining for DNA (DAPI) and myeloperoxidase positivity has also been used (149). DRAQ5 and SYTOX 
Green staining patterns can enable NET detection by both flow cytometry (150) and imaging (151). 
DRAQ5 and human neutrophil elastase immunostaining and microscopy have been used to profile 
NETs capturing Candida albicans yeast cells (152). An interesting recent approach uses the 
ImageStream® platform (Millipore Sigma, Darmstadt, Germany) detecting the morphology of DRAQ5-
stained NET DNA trails tethered to the remaining cell structure (153). 
 
 
OŶe ŵaŶ’s probe is aŶother ŵaŶ’s poisoŶ 
 
In vivo probes and drugs have to deal with adverse extracellular microenvironments (154) and a 
metabolic environment frequently determined by gene expression patterns (e.g. p450 family; (155)). 
These states can enhance or even frustrate delivery to targets (154). For example cytometry has 
revealed the DNA targeting potential of fluorescent anthraquinone-based prodrugs (156,157) in their 
response to their metabolic activation in hypoxic microenvironments (158). Flow- and image-assisted 
cytometry can profile individual molecular events in DNA damage responses (159) linked to effective 
targeting of a probe (160) of cross-resistance to a drug (161). The ability of drug molecules to quench 
Hoechst 33342-DNA fluorescence signatures can be used to track the binding of molecules with low 
fluorescence [e.g. the anti-leukemic drug 4'-(9-acridinylamino) methane sulfon-m-anisidide; m-AMSA; 
(162)] or spectrally distinct fluorescence properties (125,163). DNA targeting agents face cellular 
membrane barriers (112,164), active efflux (161) and sequestration at cytoplasmic sites (156). The 
nucleic acid target is clearly in competition with different kinds of molecules. Even the packaging of 
the genome by histone proteins into nucleosomes can alter how different DNA sites interact 
preferentially with an agent. A DNA affinic drug such as mitoxantrone (MTX) can significantly impact 
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upon chromatin protein residence and function (51,165,166), DNA topoisomerase function (167). The 
pharmacodynamic effects  of MTX appear to be dependent upon persistence at the chromatin target 
(54) an indicator that probe residence time at target is critical. Probe efflux provides information on 
cell heterogeneity that can correlate with dƌug ƌespoŶse heteƌogeŶeitǇ. The deteĐtioŶ of ͚side-
populatioŶs͛ ĐhaƌaĐteƌiziŶg steŵ Đells (168) is based on the extent of the binding-dependent shift in 
the Hoechst 33342-DNA emission spectrum (169,170). Changes in Hoechst 33342 (171,172) and 
VǇďƌaŶt® DǇeCǇĐle™ Violet (173) cellular fluorescence effectively track dye efflux capacity. The efflux 
signature of DNA interactive agents and drugs can be explored using a compartmental modelling 
approach, providing a mathematical description of the activity of the anti-cancer agent. Such models 
can take into account intracellular modification and delivery to a nuclear DNA target (27). This can 
also be extended to model the subsequent perturbation of the cell cycle (174). Smart DNA-targeted 
reporters will enable mathematical constructs of single cells that link Micro-PharmacoKinetics and 
cellular PharmacoDynamics with specific Cellular Descriptors (PK-PD-CD). Descriptors, such as 
aldehyde dehydrogenase enzyme expression (175), bring a finer cytometric dimension to early drug 
development (176).  
 
Figure 7: Chemical structure of Mitoxantrone (MTX) - an anthracenedione antibiotic with 
antineoplastic activity. Chemical structure information and properties are obtainable from the 
PubChem Substance and Compound databases (177). 
 
The problem of understanding the biological impact of a DNA targeting molecule and probe properties 
in the context of chromatin structure his exemplified here by the anthracenediones. Mitoxantrone 
(MTX; Novantrone®), (1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-
anthracenedione) is a anthracenedione - structurally related to the classical anthracyclines. MTX has 
also provided an impetus for the generation of derivatives including prodrug forms (178-181) for a 
more selective targeting of tumour cell populations (182). Its behaviour in the chromatin environment 
(166) is an exemplar of multi-level action (40). A principal mechanism of action of MTX is the persistent 
inhibition of DNA topoisomerase complexes (54). However, MTX also has a striking ability to condense 
nucleic acids by both trapping and excluding chromatin proteins (166,183). The MTX chromophore 
(Exmax 610 and 660 nm; Emmax 685 nm ; (184)) permits fluorescence microscopy and flow 
cytometry to determine uptake and nuclear distribution revealing drug resistance (185) and the 
behaviour of alkylamino-anthraquinones derivatives and their N-oxides (156). The structurally related 
far-red fluorescent DNA dyes and the nuclear counterstains DRAQ5™ (124,186-188), DRAQ7™ 
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(85,128,189-191) and the spectrally shifted  CyTRAK Orange™ (192) have applications in nuclear 
cytometry (193). The spectrally-compatible combination of the nuclear stain DRAQ5 and the anionic 
counterstain eosin also provides a dual-component fluorescent staining protocol. This is analogous to 
haematoxylin & eosin and intended for use on fresh, non-sectioned tissues (186) in clinical settings – 
an innovation loop in nuclear cytometry that now spans centuries (194). 
 
 
 
 
 
 
 
 
 
 
Conclusion 
 
In terms of nuclear cytometry there is a widening of the opportunities to deploy smart molecular DNA 
probes, not restricted by their fluorescence profiles. Novel probes offer  distinct and often unique 
properties. Molecular probe design is clearly informed by drug development highlighting a constant 
caveat for the use of vital probes, in which their biological effects can be a known unknown. The 
ambition here is to reveal fundamental aspects of nuclear function and chromatin form. New 
opportunities arise from understanding the photophysical and photochemical properties of probes in 
conjunction with the targeting of discrete biological structures while also exploiting new detection 
modalities. Downstream impact lies in the promise of methodologies that can inform chromatin 
structures and organisational levels that are targets for anticancer drugs or indeed reflect disease 
progression. Further, using these new approaches to nuclear cytometry, to describe the chromatin 
changes that occur both globally and locally during key transitions such as a somatic to pluripotent 
states (195,196), will reveal the extent to which such changes have regulatory roles in both disease 
and health. 
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